MREO
Mereo BioPharma Group plc
$0.34
+0.01 (+3.72%)
At close · Jul 2
Market Cap
$267.12M
Shares
798,093,044
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.34
Open$0.32
Day$0.32–0.34
52W$0.20–3.05
Avg vol 30d5.2M
Short int5.3M · 0.7% float · 1.6d
Short vol24%
Last earningsMar 19, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 12
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Neutral
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−64% below
+
Price vs 50-day avg
+14% above
◦
RSI (14)
58 · neutral
+
MACD trend
positive
−
52-week position
5% · near low
Sentiment · smart money
Neutral
◦
Trend (MA cross)
50d $0 › 200d $1 — 200d above 50d
−
Institutional flow
-14% holders QoQ · +14 funds added
◦
Insider flow
No net insider activity over 90 days
+
Short interest
0.67% of float · ▼ -34.5% MoM · 1.6 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
64 holders — mid 3-yr range
Fundamentals
Strong
+
EPS growth
+17% Y/Y
−
Free cash flow
$-31.0M
+
Balance sheet
net cash $41.0M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−64% below
Bearish
Price vs 50-day avg
+14% above
Bullish
RSI (14)
58 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
5% · near low
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-14% holders QoQ · +14 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.67% of float · ▼ -34.5% MoM · 1.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
64 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $0
Now $0 · 5%
52-wk high $3
vs 200-day avg -64%
vs 50-day avg +14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Total ADS equivalents | 159,131,700 | as of December 31, 2025 | — |
| Total ordinary shares issued | 795,658,504 | as of December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MREO
this stock
Mereo BioPharma Group plc
|
$267.12M | -19.7% | -100.0% | — | 0.7% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MREO | +11.3% | +0.3% | -12.8% | +5.4% | -19.7% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +9.9% | +1.6% | -20.8% | +5.6% | -28.9% |